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Small cell lung carcinoma (SCLC) is a highly lethal,
smoking-associated cancer with few known target-
able genetic alterations. Using genome sequencing,
we characterized the somatic evolution of a geneti-
cally engineered mouse model (GEMM) of SCLC
initiated by loss of Trp53 and Rb1. We identified
alterations in DNA copy number and complex
genomic rearrangements and demonstrated a low
somatic point mutation frequency in the absence of
tobacco mutagens. Alterations targeting the tumor
suppressor Pten occurred in the majority of murine
SCLC studied, and engineeredPten deletion acceler-
ated murine SCLC and abrogated loss of Chr19 in
Trp53; Rb1; Pten compound mutant tumors. Finally,
we found evidence for polyclonal and sequential
metastatic spread of murine SCLC by comparative
sequencing of families of related primary tumors
and metastases. We propose a temporal model of
SCLC tumorigenesis with implications for human
SCLC therapeutics and the nature of cancer-genome
evolution in GEMMs.
INTRODUCTION
Human tumors are believed to arise through reiterated
Darwinian cycles of spontaneous mutation and selection (Now-
ell, 1976). By the time a tumor is clinically detected, individual
tumor cells harbor numerous acquired mutational events under
selection (‘‘drivers’’) and an even greater number of events offer-
ing no selective advantage (‘‘passengers’’). The identification of
driver mutations in human cancers remains a major obstacle for
cancer genome sequencing efforts. Although several ap-
proaches have been recently described, the statistical power1298 Cell 156, 1298–1311, March 13, 2014 ª2014 Elsevier Inc.of these approaches is critically dependent on large sample
numbers in part due to high-observed mutation frequencies,
particularly in mutagen-associated cancers (Lawrence et al.,
2013).
As an example of these challenges, two recent small-cell lung
carcinoma (SCLC)-sequencing studies identified distinct novel
putative driver alterations (Peifer et al., 2012; Rudin et al.,
2012). Whether this reflects true biological differences in the
tumor cohorts or differences in analytical methods is unknown.
A limitation of these and many human cancer-genome charac-
terization studies to date is the lack of rigorous in vivo functional
validation. Studies that include functional data largely rely upon
cultured cells, which lack many hallmark features of naturally
arising tumors (Hanahan and Weinberg, 2011).
SCLC is nearly always associated with extended tobacco use
and has lagged behind other solid tumors with respect to identi-
fication of targetable driver mutations (Califano et al., 2012;
Jackman and Johnson, 2005). In addition, patients usually
present with highly advanced, metastatic disease. Although
there is often a significant response to systemic chemotherapy,
the disease invariably relapses and the median 5-year overall
survival is less than 5%. Moreover, surgical resection is rarely
performed, and the consequent lack of available SCLC tissue
is a significant barrier to molecular studies. Human SCLC harbor
mutations in TP53 and RB1 at very high frequency; therefore,
a mouse model of SCLC was generated by lung-specific
compound deletion of Trp53 and Rb1 (hereafter referred to as
‘‘PR mSCLC’’ for p53, Rb1 mutant murine SCLC; Meuwissen
et al., 2003). In the absence of tobacco-associated mutagens,
these animals develop SCLC that progresses from small neuro-
endocrine bodies (NEBs) and recapitulates many features of the
human disease, including frequent distant metastases to sites
commonly seeded by human SCLC.
We hypothesized that several features of the PR mSCLC
model were well-suited for a comparative cancer genome
sequencing study. First, unlike many models, mSCLC is initiated
by engineered deletion of two tumor suppressors (Rb and p53).
In addition, somatic tumor-genome evolution, including the
conserved oncogenic DNA copy number amplifications of
Mycl1 and Nfib, has been demonstrated during tumor progres-
sion in mSCLC (Calbo´ et al., 2005; Dooley et al., 2011). The
long latency (12–14 months) and high frequency of metastases
in this model also mirrors the progression of most adult-onset
human cancers that are believed to evolve over many years
(Jones et al., 2008). We also predicted that the absence of
tobacco mutagens would reduce the background mutation
frequency and improve statistical power to detect recurrent
driver mutations. Here, we characterize a panel of PR mSCLC
primary and metastatic tumors at single-nucleotide resolution
using exome and genome sequencing in order to elucidate
mechanisms of tumor progression and identify conserved ac-
quired somatic drivers of SCLC.
RESULTS
Murine SCLCs Harbor Complex Genomes
We generated a PR mSCLC tissue bank consisting of primary
tumors and metastases as previously described (Dooley
et al., 2011; Table S1A available online). Exome sequencing
was performed on 27 SCLC primary tumors and metastases
isolated from six individual animals with matched control DNA
isolated from tail clippings (total of 33 exomes). Fourteen tu-
mors and paired control DNA also underwent whole-genome
sequencing (WGS; total 18). Raw data were processed through
a mouse-specific analysis pipeline (Extended Experimental
Procedures).
Considering the role of previously characterized acquired DNA
copy number alterations in this model, we first identified recur-
rent somatic DNA copy number alterations in primary mSCLC
tumors (Extended Experimental Procedures; Tables S1B–S1D;
Beroukhim et al., 2007; Mermel et al., 2011). As shown in
Figures 1A–1C, the most frequent alterations in somatic DNA
copy number were whole chromosomal alterations, including
losses of Chr19 (9 of 17 primary tumors; GISTIC q value: <1 3
1015), followed by gain of Chr4 (6/17 primary tumors; GISTIC
q value: <1 3 1015). mSCLC tumors also harbored recurrent
loss of Chr8, Chr12, Chr14, and Chr16 (GISTIC q value: 8.34 3
107; <1 3 1015, <1 3 1015, and 8.34 3 107, respectively)
and gain of Chr16 (q value 1.6 3 106). In all cases, whole chro-
mosome losses were hemizygous.
We also detected focal Chr4 amplifications that harbored
well-established oncogenes previously described in PRmSCLC,
including Mycl1 (8/17 tumors; GISTIC q value: 3.7 3 107) and
Nfib (4/17 tumors; GISTIC q value 1.0 3 104; Figure 1C; Calbo´
et al., 2005; Dooley et al., 2011). We identified a recurrent focal
deletion encompassingMir200a/Mir200b and the hairy enhancer
of split (Hes2, Hes3, and Hes5) family of transcriptional effectors
of the Notch signaling pathway (q value 2.39 3 105). Whether
these amplified and deleted regions drive progression of mSCLC
remains to be tested, but analysis with GISTIC demonstrates
that these alterations occurred more frequently than expected
by chance, suggesting these events provide selective advantage
during tumor progression.
We identified genomic rearrangements in 14 mSCLC tumors
by WGS (Table S1E; Extended Experimental Procedures). Nospecific classes of rearrangements were enriched in these sam-
ples, nor were recurrent rearrangements identified in mSCLC
(Figure S1A). However, the vast majority of events occurred on
Chr4 (Figure S1B). We investigated the process underlying the
complex amplifications on Chr4 by reconstruction of individual
Chr4 maps (Figure S1C). This suggested that serial rearrange-
ment cycles, rather than a single event (i.e., chromothripsis),
led to generation of the Chr4 oncogenic amplifications in a punc-
tuated manner (Baca et al., 2013; Korbel and Campbell, 2013).
Interestingly, the tumor-suppressor loci Cdkn2a and Cdkn2b
are located between Nfib and Mycl1 on Chr4 and therefore
may pose a selective pressure against whole chromosomal
gain or chromothripsis of Chr4 as a mechanism to amplify
Mycl1 and Nfib function in this setting. PCR-based validation
of a subset of putative rearrangements suggested a high degree
of confidence in rearrangement calls (Figure S1D; Experimental
Procedures). We detected rearrangements with putative func-
tion, including a focal deletion ofMagi2, an upstream component
of the phosphatase and tensin homolog (PTEN)/phosphatidyli-
nositol 3-kinase (PI3K) signaling network (Wu et al., 2000;
Zmajkovicova et al., 2013). We also noted intrachromosomal
rearrangements generating in-frame fusions of Abl1 kinase
(Abl1-Nup214) and transcriptional regulators Cited4 (Cited4-
Asap3 and 9030409GRik-Cited4; Figure S1E).
We next identified point mutations in the exonic sequences
of 27 primary tumor and metastasis using muTect (Cibulskis
et al., 2013). Exome sequencing revealed a mean of 0.91 pro-
tein-altering point mutations per Mb sequenced, or 27.9 pro-
tein-altering mutations per tumor (Figure S2A; Table S1F). Given
the general lack of experience with these methods in model
organisms, we performed two independent validation exercises
that suggested these methods were accurate and estimates of
mutation frequencies were valid (see Extended Experimental
Procedures; Table S1G; Figure S2B).
To begin cross-species analysis of human cancer and murine
SCLC genomes, we first compared the overall frequencies of
DNA copy number alterations, point mutations, and rearrange-
ments observed in mSCLC to several human tumor types
(Extended Experimental Procedures). Interestingly, mSCLCs
exhibited a comparable frequency of genomic rearrangements
and copy number alterations compared to human cancers but
harbored a significantly lower number of point mutations (Fig-
ures 1D–1F). Although the mechanisms underlying these obser-
vations remain unclear, the low point mutation frequency is likely
in part a result of the absence of tobacco-associated mutagens.
The high frequency of rearrangements, including complex punc-
tuated rearrangements of Chr4, may be in part a reflection of p53
loss (Rausch et al., 2012). In order to specifically search for
shared driver genes in SCLC, we also compared recurrently
amplified or deleted regions withinmSCLC genomes to available
data from human SCLC genome-sequencing studies (Table
S1H; Extended Experimental Procedures; Peifer et al., 2012;
Rudin et al., 2012). Regions within Chr4 amplification and
Chr14 loss in mSCLC were conserved in human SCLC. The
region of recurrent amplification on Chr4 encompassing Mycl1
corresponded to a region of amplification on Chr1 in human
SCLC harboring MYCL1. In addition, a set of genes frequently
deleted within the Chr3p region in human SCLC, including theCell 156, 1298–1311, March 13, 2014 ª2014 Elsevier Inc. 1299
Figure 1. Genome Remodeling during mSCLC Progression
(A) Global DNA copy number alterations (CNAs) shown for mSCLC primary tumors. Blue represents copy loss; red represents copy gain. Individual tumors shown
horizontally, chromosomes depicted on vertical axis.
(B) GISTIC analysis of recurrent whole-chromosome CNAs in mSCLC identifies recurrent loss of Chr19, Chr12, Chr14, and Chr16 and recurrent gain of Chr4.
(C) GISTIC analysis of recurrent focal CNAs identifies six recurrent amplification peaks on Chr4 and a single area of recurrent copy number loss on Chr4. Genes of
interest are listed next to focal gains and losses, and the number of genes in the peak of the CNA is shown in parentheses.
(D) Comparison between mSCLC and human cancers with respect to the fraction of the genome altered by CNAs.
(E) Comparison of mSCLC and human cancers with respect to the number of rearrangements per tumor.
(F) mSCLCs exhibit a lower point mutation frequency compared to human cancers.
(G) Circos diagrams depicting whole-genome sequencing of mSCLC. Shared rearrangements between primary tumors and metastases identify lineage
relationships. Outer band representsmetaphase banding pattern; inner track showsDNA copy number alterations. Intrachromosomal rearrangements are shown
as blue (shared betweenmultiple tumors) or green (unique); interchromosomal events are shown as red lines (shared betweenmultiple tumors) or purple (unique).
See also Figure S1 and Table S1. Error bars (D–F) represent mean and SD.putative tumor suppressor FHIT, was syntenic to murine Chr14,
which was subject to recurrent hemizygous loss (Wistuba et al.,
2001).
The mechanisms that give rise to point mutations in this model
are not the focus of this work; however, we observed a note-
worthy mutation signature in mSCLC that would bear further
investigation (Figures S2C and S2D). This signature was also
dominant in the set of validated mutations (Extended Experi-
mental Procedures). Interestingly, the signature was not de-1300 Cell 156, 1298–1311, March 13, 2014 ª2014 Elsevier Inc.tected in a KrasG12D; p53-null driven mouse model of lung
adenocarcinoma (data not shown; D.G.M, G.G., and T.J., un-
published data). This suggested the mSCLC signature is unique
to this model and not a universal feature of genetically engi-
neered models or p53-null murine cancer cells. These mutations
did not occur preferentially in regions of DNA copy number
alteration or near rearrangement breakpoints (data not shown),
and therefore, we suggest that this mutational signature is the
product of an as yet unknown mechanism.
Figure 2. mSCLCs Acquire Recurrent Pten Alterations
(A) CoMut plot showing the individual mSCLC tumors on the x axis and mutation information on the y axes. Two genes are considered statistically significantly
mutated: Pten and Olfr811. Left-sided histogram shows percent of samples with a mutation in the given gene in the right side of plot. Average allelic fraction of
mutations in individual tumors shownbelowmutationplot, andChr19copystatus shownatbottomofdiagram.Numberofmutations/sampleshownon tophistogram.
(B) Pten immunohistochemistry (IHC) showing positive Pten staining in early premalignant neuroendocrine bodies (NEBs).
(C) Pten IHC depicting a Pten-negative tumor.
(D and E) Pten (D) and phospho-AKT(S473) (E) mutually exclusive IHC staining in the same mSCLC tumor.
See also Figure S2 and Table S1.mSCLCs Acquire Recurrent Alterations in the Pten
Tumor Suppressor Pathway
We identified two statistically significant recurrently mutated
genes using MutSig, Pten and Olfr811 (Figure 2A; Table S1I;
Extended Experimental Procedures). Three independent point
mutations in Pten were identified and validated (Figures S2Eand S2F). Review of individual Pten mutations provided strong
evidence for functional impact of these mutations: the T131P
mutation corresponds to a hot spot mutation site within the
catalytic core of the phosphatase domain, and the T26P and
R267-splice mutations are documented germline events in
Cowden’s syndrome (Forbes et al., 2011; Pilarski et al., 2011;Cell 156, 1298–1311, March 13, 2014 ª2014 Elsevier Inc. 1301
Tsou et al., 1998). We also identified recurrent nonsynonymous
mutations in genes encoding other Pten signaling components:
Magi1, a scaffolding protein involved in shuttling Pten to the
plasma membrane; Eef2k, a downstream PI3K effector involved
in the regulation of translation elongation; and Ikbkb, a gene
product linking nuclear factor kB to PI3K signaling (Ha¨cker and
Karin, 2006; Kotelevets et al., 2005; Zmajkovicova et al., 2013).
Each of these genes was mutated in two clonally independent
tumors. This suggests that disruption of Pten signaling at multi-
ple points in the pathway may promote tumor progression in
mSCLC. Indeed, ingenuity pathway analysis of all protein-
altering point mutations identified in mSCLC revealed enrich-
ment of the PI3K/PTEN networks (Table S1J). In addition,
PTEN alterations have been reported in human SCLC, further
supporting a conserved tumor-suppressive role (Dacic et al.,
2002; Forgacs et al., 1998; Yokomizo et al., 1998).
In addition to alterations in Pten signaling, we detected
recurrent mutations in the semaphorin (Sema5b, Sema3c, and
Sema4f) and ephrin (Epha5 and Epha7) gene families, which
regulate cellular migration during embryonic development. Inter-
estingly, axonal guidance pathways have been implicated as
drivers in pancreatic cancer by recent cross-species sequencing
and transposon-based screens in pancreatic cancer (Biankin
et al., 2012).
We also compared genes mutated in mSCLC to two recent
human-SCLC-sequencing reports (Peifer et al., 2012; Rudin
et al., 2012). Because the mutational burden in human SCLC
was high, we analyzed genes mutated in mSCLC relative to the
published significantly mutated, hot spot, and clustered genes
from both studies (Table S1K). Several genes were mutated in
both mSCLC and human SCLC, including PTEN and EPHA7.
However, whether this is the product of the high mutation fre-
quency observed in human SCLC or reflects a conserved func-
tional role for shared events remains to be determined. Of
note, only one gene besides TP53 and RB1, TMEM132D, was
reported as significantly mutated by both human studies. This
highlights the challenges associated with genomic analysis of
highly mutated human cancer genomes.
The genomic location of Pten, Chr19 28.14cM, also raised the
possibility that Chr19 loss, themost frequent observed alteration
in DNA copy number in mSCLC, may be driven primarily by
impairment of Pten function. All tumors harboring Pten point
mutations also exhibited evidence for loss of Chr19, suggesting
that complete loss of Pten function may be advantageous and
occur via multiple mechanisms in mSCLC.
To further define the frequency and timing of Pten loss in
mSCLC, we examined Pten expression by immunohistochem-
istry (IHC) in early neuroendocrine bodies and in advanced
tumors (Figures 2B–2D). Qualitative analysis of Pten staining
revealed that the majority of high-grade mSCLCs exhibit com-
plete loss of Pten as compared to precursor neuroendocrine
bodies (Figure S2G), supporting the notion that Pten loss may
facilitate tumor outgrowth. We also observed several mSCLC
tumors with a mixed Pten status (Figure 2D). Although PI3K
independent functions of Pten have been demonstrated, a hall-
mark of Pten loss is activation of the canonical PI3K/AKT
signaling pathway. Therefore, we assessed Pten status and
PI3K signaling by IHC for Pten and phospho-Akt (pAktS473).1302 Cell 156, 1298–1311, March 13, 2014 ª2014 Elsevier Inc.Pten-negative areas showed a reciprocal increase in pAkt stain-
ing by IHC (Figures 2D and 2E), implicating canonical PI3K
signaling as a major output of Pten loss during mSCLC progres-
sion. In addition, a tumor harboring an inactivating Pten point
mutation (T131P), and another sample with a Magi2 deletion,
did not show loss of Pten IHC staining but exhibited increased
pAkt staining (data not shown).
To test whether mutations in upstream signaling components
impact canonical PI3K signaling in SCLC, we depleted Magi1
using small hairpin RNAs (shRNAs) in mSCLC cell lines. Consis-
tent with this model, Magi1 knockdown resulted in increased
pAkt signaling uniquely in cells with wild-type Pten status (Fig-
ure S3A). We detected modestly diminished cellular growth in
response to Magi knockdown in mSCLC cells, independent of
Pten status, suggesting that Magi1 was required for PI3K-
independent functions in mSCLC cells, consistent with prior
studies (Wegmann et al., 2004).
Pten Deletion in mSCLC Accelerates Tumorigenesis
In order to define the role of Pten loss in mSCLC, we crossed a
cre-regulated, conditional Pten allele into the PR mSCLC model
(hereafter referred to as PRPt for p53, Rb1 and Pten; Lesche
et al., 2002). To assess tumor growth kinetics in living animals,
a cohort of PRPt animals also harbored a cre-activated lucif-
erase reporter allele. We initiated tumors in PRPt (Trp53FL/FL;
Rb1FL/FL; PtenFL/FL), PRPt/+ (Trp53FL/FL; Rb1FL/FL; PtenFL/+),
and PR (Trp53FL/FL; Rb1FL/FL; Pten+/+) animals by intratracheal
administration of adenovirus expressing cre recombinase under
the control of the neuroendocrine-specific CGRP promoter in
order to selectively delete Rb1, Trp53, and Pten in pulmonary
neuroendocrine cells (Sutherland et al., 2011). Measurement of
in vivo luciferase activity at 4, 5, and 6 months posttumor induc-
tion revealed acceleration of tumor growth in PRPt versus PR
animals (Figures 3A and 3B).
We also assessed tumor burden in cohorts of PR, PRPt/+,
and PRPt animals 5 months following tumor induction using
small-animal MRI. We detected significantly greater tumor
volume in PRPt animals (Figures 3C and 3D). Furthermore,
we observed a significant reduction in mSCLC tumor latency
and significantly reduced overall survival in PRPt (6.3 months)
and PRPt/+ (8.3 months) compared to PR animals (17.5 months;
Figure 3E). We confirmed the in vivo imaging results in cohorts
of PR, PRPt/+, and PRPt animals at 5 months postinduction
using quantitative histology, which showed a striking difference
in tumor burden (Figure 3F). To ensure a change in tumor
spectrum did not underlie the acceleration of tumor progression
in PRPt animals, we performed histological analysis of tumor-
bearing lung sections. The majority of the tumors identified
displayed neuroendocrine features and stained positive for
the neuroendocrine marker CGRP, consistent with a role for
Pten loss as a driver of SCLC progression (Figures S3B, S3E,
and S3H).
The state of PI3K signaling was assessed using phospho-
specific IHC for Akt. High levels of pAkt were present in PRPt
tumors at 6 months posttumor induction (Figures S3D and
S3G). Pten loss and activated Akt signaling are known to pro-
mote proliferation and oppose apoptosis. Therefore, we assayed
apoptosis and proliferation by IHC. We detected a significant
Figure 3. Pten Deletion Accelerates mSCLC Progression
(A) Representative bright field/luminescence images.
(B) Quantitation of luminescence (photon flux) of PR and PRPt animals. Relative photon flux calculated by normalizing all time points per animal to initial
measurements at 4 months postinfection.
(C) Representative axial MRI sections of PR and PRPt animals at 5 months postinfection.
(D) MRI tumor volume measurements (mm3).
(E) Overall survival of SCLC cohorts.
(F) Relative tumor burden determined by quantitative hematoxylin and eosin staining microscopy. **p < 0.01.
(B, D, and F) Mean and SEM shown by error bars. See also Figure S3 and Table S1.increase in phospho-histone H3, a mitotic marker, in the PRPt
as compared to PR tumors 6 months after tumor initiation (Fig-
ure S3I). Conversely, we observed a decrease in the levels of
cleaved caspase-3, a marker of apoptosis, in Pten-null tumors(Figure S3J). These data support the tumor-suppressive role of
Pten in mSCLC and provide evidence that loss of Pten can drive
tumor progression, in part through increased proliferation and
diminished apoptosis.Cell 156, 1298–1311, March 13, 2014 ª2014 Elsevier Inc. 1303
Figure 4. Pten Deletion Alters Genome Evolution in mSCLC
(A) CNA heatmap for PRPt mSCLC tumors analyzed by SegSeq.
(B) GISTIC results for recurrent CNAs. Note the absence of Chr19 deletion and presence of Chr4 focal amplification.
(C) Chr19 copy number map for all primary tumors analyzed. Genotype is listed to the right. Analysis method (CapSeg or SegSeq) listed to the left.
See also Figure S4 and Table S1.Combinations of Engineered Events Alter the Path of
mSCLC Genomic Evolution
Detection of recurrent Pten point mutations and the in vivo func-
tional studies provide evidence that Pten loss is a crucial event
during mSCLC tumor progression. It is therefore reasonable to
hypothesize that Pten mutation is the driving force behind
Chr19 loss in PR mSCLC. To test this notion, we utilized PRPt
triple-mutant mSCLC to characterize tumor-genome evolution
in the context of Pten loss at the time of tumor initiation. We
performed low-read-depth whole-genome sequencing of 11
PRPt (nine primary tumors and two metastases) and two
PRPt/+ mSCLC tumors to characterize acquired DNA copy
number alterations. These tumors were of similar size and histo-
logic grade to PR tumors used in our initial analyses. Consistent
with the hypothesis that selective advantage of Pten impairment
underlies loss of Chr19 in thismodel, all PRPtmSCLC exhibited a
DNA copy number of two for Chr19 (Figures 4A and 4B; Table
S1L). Therefore, deletion of a single exon of Pten provided the
selective advantage for loss of an entire chromosome in this
model. Interestingly, two PRPt/+ tumors exhibited hemizygous1304 Cell 156, 1298–1311, March 13, 2014 ª2014 Elsevier Inc.loss of Chr19, and review of the sequencing reads demonstrated
that the mutant chromosome 19 was retained, suggesting addi-
tional selective advantage of complete Pten loss (Figure 4C).
Despite the decreased tumor latency and absence of Chr19
loss in the PRPt mSCLC tumors, we detected recurrent focal
amplifications on Chr4 in these samples (Figure 4B; Table
S1M). Although GISTIC analysis did not show Mycl1 within the
predicted amplification peak, our sequencing read depth was
designed to detect whole-chromosome gains and losses rather
than focal alterations. Therefore, we used quantitative PCR
to assess Mycl1 amplification in these samples. Mycl1 copy
number was amplified in these tumors, suggesting an important
role for Mycl1 amplification during the initial outgrowth of
mSCLC (Figure S4).
Intratumoral Clonal Heterogeneity in mSCLC
We established tumor lineage relationships between primary
tumors and metastases from individual mice by identifica-
tion of shared DNA rearrangements and point mutations
(example, Figure 1G). Using this approach, we identified related
primary-metastasis pairs from six animals, including three tumor
families from which we sequenced multiple metastatic lesions
(Table S1N). Although shared somatic mutations can identify
basic lineage relationships between tumors, more sophisticated
methods are required to reconstruct the clonal architecture of tu-
mor progression.We first examined the allelic fraction of somatic
mutations in mSCLC tumors. The observed distribution of allelic
fractions for all somatic mutations observed in primary tumors
revealed an abundance of mutations with low allelic fraction.
However, metastases exhibited a greater proportion of muta-
tions with high allelic fraction, consistent with a clonal bottleneck
during metastatic seeding (Figures S5A and S5B).
The allelic fraction of a mutation depends on tumor purity,
local DNA copy number, and the fraction of cells in a tumor
that harbor the mutation. Therefore, in order to systematically
characterize the clonal structure of PR mSCLC tumors, we
used ABSOLUTE, a method that utilizes the copy number of
DNA in the vicinity of a mutation and tumor purity to estimate
the fraction of cancer cells harboring a given mutation, called
the cancer cell fraction (CCF) (Carter et al., 2012; Landau
et al., 2013). ABSOLUTE analysis confirmed the presence of
clonal heterogeneity in all mSCLC tumors, with a range of two
to five subclones within individual tumors (Tables S1O–S1Q).
We compared the CCF for individual mutations between pri-
mary tumors and metastases using two-dimensional plots in
order to define the clonal structure of mSCLC (Figure 5). Clonal
lineages were identified by clustering mutations exhibiting
shared CCF (Landau et al., 2013). As a tumor subclone colo-
nizes metastatic sites, it passes through population bottlenecks
in which the preexisting mutations are enriched and additional
mutations are subsequently acquired. We denote clonal line-
ages by a common nomenclature (for example, clone 1a is a
descendent of clone 1 and clone 1b is a descendent of clone
1a, whereas clone 2 is a related, but independent, sibling of
clone 1). The number of mutations delineating each clonal
transition is shown in Figure 5, and all mutations in the tumor
families detailed below are annotated with the CCF and
subclone assignment in Tables S1O–S1Q.
Parallel Seeding of Multiple Liver Metastases in mSCLC
From animal 3588, we sequenced three primary tumors and
two independent liver metastases (Figures 5A–5E; Table
S1O). Both liver metastases (3588-C1 and 3588-M1) shared
17 clonal mutations with one primary tumor, 3588-T1, demon-
strating that these arose from a single primary tumor. 3588-T1
harbored two independent subclones existing at approximately
0.2 CCF (clone 1, purple) and 0.25 CCF (clone 2, blue; see Fig-
ures 5B–5D). Interestingly, both liver metastases originated
from closely related subclones (clone 1a-M1 and clone 1a-
C1) that were descended from a common ancestor (clone
1a). Clone 1a was a descendent of clone 1, as demonstrated
by the enrichment of the CCF of clone 1 mutations in both
descendent metastases (Figures 5B and 5D, purple clusters).
We could not discriminate if clone 1a was present in the pri-
mary tumor outside of the sampled region or below the level
of detection or whether it first seeded another site prior to
founding the liver metastases. Each metastatic lesion also
continued to evolve during outgrowth as evidenced by acquisi-tion of subclonal mutations (clone 1a-M1-a, green, and clone
1a-C1-a, red; Figures 5B, 5D, and 5E).
Polyclonal Seeding of Local Lymph Node Metastases in
mSCLC
We sequenced five primary tumors, one thoracic lymph node
metastasis, and one liver metastasis from animal 3151. Again,
in this case, both metastases shared acquired clonal mutations
with one primary tumor, confirming their shared origin (light
gray clusters, Figures 5G and 5I; Table S1P). Comparison of
the primary tumor (3151-T1) and lymph node metastasis (3151-
N1) revealed a large cluster of mutations (green-light purple
central cluster, Figure 5G) present at subclonal CCF in both the
primary tumor and metastasis. A single-cell-origin model would
require mutations to become clonal in a descendent metastasis.
Therefore, these data were inconsistent with monoclonal origin
of the lymph node metastasis (Figures 5F–5J). Comparison of
the lymph node and liver metastases (3151-M1) revealed that
only a subset of mutations in this cluster was sharedwith the liver
metastasis (Figures 5H and 5I; clone 1 mutations). In addition,
mutations in clone 1a from the nodal metastasis (3151-N1)
were enriched to a clonal CCF (1.0) in the distant liver metastasis
(Figure 5I). We therefore concluded that two related primary
tumor subclones (clone 1, light purple, and clone 2, green; Fig-
ure 5G) seeded the lymph node metastasis and gave rise to
clones 1a and 2a (Figure 5G). However, only one of these clones
spread to the liver (clone 1b, a direct descendent of clone 1a
from the lymph node metastasis; Figure 5J). Clone 1b was the
founding clone of the liver metastasis and was a recent descen-
dent of clone 1a, as shown by the enrichment of clone 1a CCF
(0.5 to 1.0) in the distant liver metastasis (3151-M1; Figure 5I).
We cannot formally exclude the possibility that two highly related
clone 1 cells spread directly from the primary tumor to both the
lymph node and liver metastasis. However, in this scenario, we
would not have expected all clone 1a mutations to be shared
with the liver metastasis, as we observed. Therefore, the most
parsimonious explanation for the observed data is that two pri-
mary tumor subclones first seeded the nodal metastasis and
that clone 1a further evolved into clone 1b and founded a tertiary
liver metastasis.
Two primary tumors and one lymph node metastasis were
sequenced from animal 984. Shared somatic mutations demon-
strated that primary tumor 984-T3 founded the lymph node
metastasis 984-M1 (Table S1Q). Analysis of this relationship
using ABSOLUTE revealed that clone 1 (dark gray, Figures 5K
and 5L) was present at subclonal CCF in both the primary tumor
and metastasis. This pattern is also inconsistent with mono-
clonal origin of the nodal metastasis and indicated that multiple
primary tumor (984-T3) subclones (clone 1, dark gray, and clone
2, red) spread to the local draining lymph node. Although clone 2
mutations were not detected in the primary tumor, the presence
of shared clonal mutations between 984-T3 and 984-M1 (light
gray cluster, Figure 5L) confirmed that both subclones within
the local lymph node arose from a single primary tumor
(984-T3; Figure 5M). In each of these analyses, althoughwe iden-
tified specific mutations present within individual subclones, our
data did not address whether individual mutations acted as
drivers or passengers.Cell 156, 1298–1311, March 13, 2014 ª2014 Elsevier Inc. 1305
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DISCUSSION
Comparative Genomics to Identify Driver Genes in
Cancer
A longstanding goal of cancer genetics has been to exploit the
evolutionary conservation of the major tumor-suppressive and
proto-oncogenic cellular pathways between humans and mice
for biological discovery and preclinical modeling. Recently, this
has included analysis of acquired mutations in the genomes of
mouse cancer models. For example, focused DNA sequencing
of known proto-oncogenes in genetically engineered mouse
models initiated by ‘‘weak’’ cancer initiators has identified
somatically acquired activating mutations in Hras and Notch1
(O’Neil et al., 2006; Podsypanina et al., 2004). In addition,
small-scale exome and genome sequencing of murine models
of leukemia and breast cancers has identified conserved
somatic Jak1 and Trp53 mutations (Wartman et al., 2011; Yuan
et al., 2012).
The present study is to our knowledge the most complete
description of the somatic genome of a genetically engineered
mouse cancer model to date and also quantitatively assesses
intratumoral clonal heterogeneity and clonal evolution during
metastatic colonization. In the absence of tobacco mutagens,
we detected relatively few somatic point mutations compared
to human SCLC andmutagen-inducedmurine tumors (Matsush-
ita et al., 2012). The reduced mutational ‘‘noise’’ facilitated iden-
tification of Pten loss as an important driver of tumor progression
in mSCLC. We detected recurrent somatic alterations targeting
Pten, including point mutations previously described in human
cancer and Cowden syndrome. In addition, we detected ac-
quired point mutations in other components of the PTEN/PI3K
pathway, including Magi1, Eef2k, Ikbkb, Insr, and Bcar1. The
majority of PR mSCLC tumors harbor a mutation in this pathway
and/or Chr19 loss. We also provide a functional validation of the
role of Pten by compound deletion of Pten in the autochthonous
mSCLCmodel. These results are consistent with a prior publica-
tion, suggesting engineered Pten loss accelerates early tumori-
genesis in a similar SCLC model (Song et al., 2012), and we
additionally characterize the effect of Pten deletion at all stages
of SCLC progression, including a dramatic decrease in survival
of PRPt animals.
Recent sequencing of human SCLC identified multiple
mutations in the PTEN/PI3K pathway, including PTEN, PIK3CB,
PIK3R3,MAGI1, andMAGI2mutations. Although PTEN was not
identified as a recurrent target of deletion in SCLC, Chr10 copy
number loss encompassing PTENwas evident in one study (Pei-
fer et al., 2012). In addition, prior studies have demonstrated
PTEN alterations in approximately 20% of SCLC (Dacic et al.,Figure 5. Clonal Evolution of mSCLC during Metastatic Spread
Each tier (A–E, F–J, and K–M) shows ABSOLUTE analysis of related primary andm
(K) shows unclustered CCF results for individual mutations in tumor pairs. Each
mutation. Middle plots (B, D, G, I, and L) show the 95% confidence intervals fo
subclones. Clonal models based on ABSOLUTE results are shown in (E), (J), and (M
the data. In all panels, cloud color denotes membership in corresponding node (c
(purple) from the primary tumor seeded two independent liver metastases. (F an
seeding a lymph node metastasis. Clone 1b (purple), a descendent of clone 1a, s
results showing polyclonal seeding of a lymph node met (gray, clone 1a, and red
See also Figure S5 and Table S1.2002; Forgacs et al., 1998; Yokomizo et al., 1998). Therefore,
we suggest that PR mSCLC models a subclass of human
SCLC harboring alterations in the PTEN pathway.
Our data support a model in which Pten acts primarily as a
classical, rather than haploinsufficient, tumor suppressor in
mSCLC. First, Pten protein expression was lost completely in
the majority of high-grade SCLC. In addition, all Pten point
mutations occurred in tumors with copy number loss at Chr19,
suggesting that Pten functionwas completely abrogated in these
cells. Finally, PRPt/+ animals showed evidence for loss of the
wild-type (WT) Pten allele, suggesting additional selective
advantage of complete Pten loss.
Single Locus Control of Chromosomal Alterations in
Cancer
Whole-chromosome gains and losses are frequently observed
in human cancers, yet it remains unclear whether the selective
advantage for these events results from one or multiple loci.
Several studies in mouse models have suggested that multiple
loci confer selective advantage for whole chromosome gain
and loss. For example, Kras-LA2 animals developed sponta-
neous lung adenomas, and these tumors frequently exhibited
whole-chromosome gains of the LA2-bearing mutant Chr6,
whereas focal Kras-LA2 amplifications were uncommon
(Sweet-Cordero et al., 2006; To et al., 2011). This led to the spec-
ulation that additional oncogenic Chr6 loci are under selection,
including other components of Mapk signaling (To et al., 2011).
In addition, prior studies of radiation-induced lymphomas from
Trp53+/ animals identified frequent loss of heterozygosity
(LOH) at Chr19 and focal deletions involving Pten (Mao et al.,
2003). Interestingly, whole-chromosome loss of Chr19 was
also noted in Pten+/ and Pten+/; Trp53+/ lymphomas
and was interpreted as evidence for the existence of additional
tumor-suppressor loci.
The data presented in this study implicate a single gene,
Pten, at the driving force behind loss of Chr19 in mSCLC. Of
note, Mao et al. (2004) showed frequent whole-chromosome
loss of Chr3 in radiation-induced lymphomas in Trp53+/
mice and identified Fbxw7 as a candidate tumor suppressor
in a small focal deletion. Heterozygous loss of Fbxw7 acceler-
ated tumorigenesis and abrogated Fbxw7 LOH, which was
inferred to reflect maintenance of the entire chromosome. How-
ever, these studies restricted LOH analysis to the Fbxw7 locus.
The data presented here extend the concept that a selective
advantage for impairment of a single locus can drive loss of
an entire chromosome and definitively demonstrate retention
of Chr19 in PRPt mSCLC using whole-genome methods. The
fact that no PRPt tumor analyzed exhibited DNA copy numberetastatic tumors in an individual animal. Left column of plots (A), (C), (F), (H), and
cloud represents the 95% confidence interval of the predicted CCF for each
llowing a Bayesian clustering procedure that groups mutations into predicted
). Dashed lines represent assumed transitions that are not directly observed in
lone) in the model diagram. (A–D) CCF results demonstrating a single subclone
d G) shows multiple subclones from the primary tumor (clone 1 and clone 2)
eeded a tertiary liver metastasis from the lymph node (H and I). (K and L) CCF
, clone 2).
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Figure 6. Model of SCLC Tumorigenesis
Stepwise acquisition of recurrent driver mutations
identified by comparative SCLC sequencing
(D1–D4) promotes murine SCLC progression from
the pulmonary neuroendocrine cell to bona fide
SCLC. As additional drivers are engineered into
the mouse model, tumor latency is reduced and
progression is accelerated. P, passenger muta-
tions fixed in the tumor population during pro-
gression through the series of bottlenecks.loss of Chr19 is a powerful demonstration that loss of the Pten
tumor suppressor is the driving selective mechanism behind
loss of Chr19 in PR mSCLC.
Patterns of Clonal Progression in mSCLC
The description of clonal evolution between primary tumors
and metastases in solid human malignancies has been achieved
primarily by sequencing several distinct tumor regions (Campbell
et al., 2010; Gerlinger et al., 2012; Yachida et al., 2010). However,
in contrast to most human biopsies, which sample only a small
part of a tumor, we utilized approximately 50% of the individual
mSCLC tumor mass for nucleic acid preparation. Thus, a large
fraction of tumor sampling coupled with a deep sequencing
coverage (approximately 1003) may have helped elucidate the
patterns of clonal evolution between primary tumors and metas-
tases in the mSCLC model. We also capitalized on the high fre-
quency of macroscopic metastases in the mSCLC model and
our ability to harvest these diverse sites of disease at animal
necropsy. We believe our finding of spread of multiple primary
tumor subclones to a local lymph node metastasis is un-
precedented and the first demonstration of polyclonal seeding
of metastases using deep sequencing. Considering the role of
the metastatic niche in mediating treatment resistance (Gilbert
and Hemann, 2010), the fact that multiple tumor subclones
establish themselves in environments such as the lymph node
may have therapeutic implications.
We provide evidence of spread of a tumor subclone from a
lymph node metastasis to a distant site (Figure 5J). Sequential
spread of metastasis from one site to another has also been
demonstrated in human pancreatic cancer (Campbell et al.,
2010; Yachida et al., 2010). These and our data raise the possi-
bility that lymph nodes can act as the site of collection of multiple
tumor subclones and may serve as a gateway for distant metas-
tases. These data are consistent with the prognostic implication
of sentinel lymph node biopsy in several cancer types (Chen
et al., 2006). However, whether seeding of lymph node metas-
tases prior to systemic dissemination is a more uniform property
of cancer metastasis will require additional studies. In addition,
it will be important to determine if additional genetic and or1308 Cell 156, 1298–1311, March 13, 2014 ª2014 Elsevier Inc.epigenetic alterations acquired in the
local lymph node microenvironment
contribute to systemic dissemination.
The ability to illuminate the dynamic
clonal architecture within metastatic
mSCLC tumors highlights the opportunityto more completely dissect clonal metastatic progression in
this experimentally tractable system.
A Model for Tumorigenesis in SCLC
The genomic and functional data presented here begin to estab-
lish a framework for tumorigenesis in SCLC (Figure 6). The near-
ubiquitous presence of TP53 andRB1mutations in human SCLC
suggests that these are among the earliest events in these
tumors. In this genetic context, we believe Mycl1 amplification
events provide a strong proliferative advantage. Although the
clonality analysis described in this study did not allow for charac-
terization of high-level amplifications, the ease of detection of the
Chr4 amplifications suggests that these amplifications arise
during early outgrowth of the primary tumor. In addition, the
occurrence of focal Chr4 amplifications in the setting of engi-
neered Pten deletion is a strong demonstration of the requisite
nature of Mycl1 amplification in early mSCLC outgrowth. These
data also suggest that Pten mutations are selected for at later
stages of tumor progression, a notion supported by our Pten
IHC analysis showing tumors with areas both positive and nega-
tive for Pten expression.
Therapeutic targeting of Pten signaling with available high-
potency inhibitors of PI3K might therefore be warranted for
human SCLC. However, although we detect increased phos-
pho-Akt in advanced mSCLC, it is not certain that the effects
of Pten loss are entirely mediated via increased PI3K activity.
In addition, increased MYC DNA copy number or gene expres-
sion has been shown to mediate primary resistance to PI3K inhi-
bition (Ilic et al., 2011; Shepherd et al., 2013). Considering the
frequent occurrence of Chr4 amplifications involving Mycl1,
combination therapy targeting L-myc or biological effectors of
L-myc may be necessary to achieve effective responses.
Implications for Tumor Evolution in Mouse Cancer
Models
Characterization of PR tumors by exome and genome
sequencing revealed a highly molded somatic genome with a
low somatic point mutation frequency relative to human cancers.
Interestingly, PRPt tumors exhibited a less-complex tumor
genome by DNA copy number analysis. This may reflect the
addition of a third driver event (Pten loss) at tumor initiation
that bypasses a critical bottleneck during tumor outgrowth.
This notion is supported by previous studies showing recurrent
acquisition of activating oncogene mutations in models initiated
by transgenes with relatively modest impact on proliferation
(Podsypanina et al., 2004). Therefore, although the initiating
engineered mutations are often credited with the entire tumor
phenotype, somatically acquired events should be considered
when interpreting results of both discovery efforts and preclinical
studies using mouse cancer models. The work described here
demonstrates the potential of harnessing the shared evolution
of GEMMs and human cancers using comparative genome
sequencing to identify acquired drivers of cancer progression
and dissect stepwise tumorigenesis.
EXPERIMENTAL PROCEDURES
Mouse Model
p53fl/fl;Rbfl/fl and p53fl/fl;Rbfl/fl;Rosa26LSL-Luc/LSL-Lucmice have been previously
described (Dooley et al., 2011; Rosa26LSL-Luc/LSL-Lucmice are from E. Jackson
and T.J., unpublished data). To obtain p53fl/fl;Rbfl/fl;Rosa26LSL-Luc/LSL-Luc;
Ptenfl/fl mice, we obtained Ptenfl/fl animals from Jackson Laboratories
(Ptentm1Hwu/j; Lesche et al., 2002). Tumors were initiated by adenoviral delivery
of Cre, as described previously (DuPage et al., 2009). The Massachusetts
Institute of Technology (MIT) Institutional Animal Care and Use Committee
approved all animal studies and procedures. Primary tumors and metastases
from the mouse model were dissected and snap-frozen for DNA and/or RNA
isolation as previously described (Dooley et al., 2011). In parallel, part of
each tumor was kept for histology to verify SCLC features. Live-animal imaging
was performed using an IVIS Spectrum (PerkinElmer) and Varian 7T/310/ASR
MRI system (Varian/Agilent Technologies).
Genome, Exome Sequencing
Whole-exome sequencing was performed as previously described (Gnirke
et al., 2009). Whole-genome sequencing was performed using a protocol
developed for human whole-genome studies (Berger et al., 2011). Low-
coverage whole-genome sequencing and DNA copy number analysis was
performed as previously described (Dooley et al., 2011). Mutations were
identified using MuTect (Cibulskis et al., 2013). Recurrence was assessed
using MutSig 1.0 with minor modifications for mouse data (Berger et al.,
2011; Getz et al., 2007). All somatic mutations were reviewed manually,
and validation of selected mutations was performed by targeted resequenc-
ing using microfluidic PCR (Access array system; Fluidigm) and the MiSeq
sequencing system (Illumina). Genomic rearrangements were identified by
dRanger (Berger et al., 2011). DNA copy number alterations were identified
from exome data using CapSeg (A.M., B. Hernandez, M. Meyerson, G.G.,
and S.L.C., unpublished data), and GISTIC 2.0 was used to identify
recurrent alterations (Beroukhim et al., 2010; Mermel et al., 2011). SegSeq
was used to identify copy number alterations (CNAs) from WGS data
(Chiang et al., 2009). See Extended Experimental Procedures for additional
details.
Immunohistochemical Analysis
IHC was performed on formalin-fixed paraffin-embedded 4 mm sections using
the ImmPRESS Peroxidase Polymer Detection Kit (Vector Laboratories) with
recommended dilutions of primary antibodies (see Extended Experimental
Procedures).
Murine SCLC Cell Line Functional Experiments
Murine SCLC cell lines were maintained as previously described (Dooley et al.,
2011). Broad TRC shRNAs (shMagi1_83: TRCN0000079083, shMagi1_83:
TRCN0000079084) were used for Magi1 knockdown. Following infection
with Magi1 or control shRNA-expressing lentiviruses, cells were selectedusing puromycin (Sigma). After puromycin selection, cells viability was as-
sessed by Cell Titer Glo (Promega).
ABSOLUTE Analysis and Deductive Logic of Clonal Evolution
Mapping
ABSOLUTE was performed as previously described (Carter et al., 2012;
Landau et al., 2013). All mutations that define clonal lineages underwent exten-
sive manual review using IGV (Robinson et al., 2011) to ensure models were
generated using high-confidence mutations.
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